Consultancy.uk Feature — Stratence Partners after EPA Amsterdam 2026

Consultancy.uk featured Stratence Partners after EPA Amsterdam 2026, highlighting why pharmaceutical and MedTech organizations must rethink how pricing, market access, commercial execution, data, and AI operate together as one integrated commercial decision system.

Beyond Pricing Pressure: Why Pharma Needs Integrated Commercial Decision Systems

Consultancy.uk features Stratence Partners after EPA Amsterdam 2026

Healthcare organizations are operating under unprecedented commercial pressure.

Pharmaceutical and MedTech companies are simultaneously facing pricing compression, increasing reimbursement complexity, fragmented commercial systems, tender-driven competition, and growing demands for faster executive decision-making.

Yet many organizations continue managing pricing, market access, commercial execution, and analytics as disconnected functions.

The consequence is not simply operational inefficiency.

It is structural margin erosion, slower strategic response, inconsistent execution, and reduced confidence in commercial decisions.

Following EPA Amsterdam 2026, Consultancy.uk featured Stratence Partners and Fernando Ventureira, CEO of Stratence Partners, in an article focused on how organizations can move from fragmented pricing management toward integrated, AI-Powered commercial decision systems.

The discussion goes far beyond pricing itself.

The real issue is that many organizations still lack an integrated commercial decision architecture capable of aligning:

• Strategy

• Pricing

• Market Access

• Commercial Execution

• Data Management

• AI-Powered Decision Support

At Stratence Partners, we believe Commercial Transformation is no longer about isolated initiatives.

It requires a structured framework where pricing governance, commercial execution, and AI-supported decision systems operate together as one coherent economic model.

Because the objective is not more dashboards.

The objective is:

• Faster executive alignment

• Stronger Gross-to-Net transparency

• Better pricing governance

• Higher confidence in commercial decisions

• Sustainable profitability improvement

Congratulations to Fernando Ventureira and the entire international Stratence Partners leadership team:

Gary Kieffer – Aleksandar Ruzicic – David Whitaker – Greg Varner – Eduardo Kühnel – Martin Verebes – Borislav Antonov – Alberto Ortiz – David Diaz – Francesc Sola – Niels Skov – Israel Fuentes – Navin Singh – Krishna Chaitanya.

Read the Consultancy.uk article here:

https://www.consultancy.uk/news/44030/navigating-price-pressures-in-healthcare-with-data